海思科医药集团股份有限公司关于获得创新药HSK47388片新适应症《药物临床试验批准通知书》的公告

Group 1 - The core point of the article is that Haikang Pharmaceutical Group has received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK47388 for a new indication related to autoimmune diseases [1][4] - HSK47388 is an orally administered, potent, and highly selective drug developed by the company, showing significant efficacy in preclinical studies on rat models of enteritis, with good tolerability and a large safety window [1][4] - The approval for clinical trials represents a new opportunity for HSK47388 in the treatment of autoimmune diseases, potentially providing a new therapeutic option for patients [1]